CAMBRIDGE, Massachusetts and BASEL, Switzerland, Feb. 21, 2019 /PRNewswire/ -- Enzyvant, a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases, today announced the appointment of Rachelle Jacques as Chief Executive Officer.
Ms. Jacques joins Enzyvant from Alexion where she most recently served as Senior Vice President and Global Franchise Head of Complement. Previously, Ms. Jacques was Vice President of U.S. Hematology Marketing at Shire and Baxalta and Vice President, Business Operations for the Global Bioscience Business Unit at Baxter International.
"Rachelle is a proven leader and operator with deep experience bringing valued medicines to market in complex, fast-moving business environments," said Myrtle Potter, Vant Operating Chair at Roivant Pharma and Chair of Enzyvant's Board of Directors. "We are thrilled that Rachelle is joining Enzyvant as the company prepares for the potential commercialization of Enzyvant's first therapy."
"This is an exciting and pivotal time to join Enzyvant, and I'm looking forward to working alongside this team who share my passion and sense of urgency for bringing much needed therapies to those with rare diseases," said Ms. Jacques. "The company has made great strides since it was founded in 2016. I'm excited to build on that foundation as we enter this next phase of growth."
Ms. Jacques succeeds Dr. Alvin Shih as CEO. Dr. Shih led Enzyvant since November 2016, shortly after the company's founding. Dr. Shih will continue to be an advisor to the company. Under his leadership, RVT-802 became the first investigational treatment to be granted both Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations by the FDA.
"We thank Alvin for helping to lay the foundation for a strong, rare disease company and for leading Enzyvant to this important juncture. Enzyvant will benefit from his continued involvement as an advisor," said Ms. Potter.
Enzyvant, a wholly-owned subsidiary of Roivant Sciences, is a biotechnology company focused on developing transformative therapies for patients with rare diseases. Enzyvant leverages the Roivant platform to develop therapies that address high unmet medical needs while driving greater efficiency in research, clinical development, and commercialization. Enzyvant is currently in the process of completing a rolling Biologics License Application submission with the FDA for RVT-802, an investigational tissue-based therapy for the treatment of primary immunodeficiency associated with congenital athymia. Enzyvant is also preparing to initiate a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease. For more information, please visit www.enzyvant.com.
About Roivant Sciences
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit www.roivant.com.
Tamara Joseph, General Counsel, email@example.com
Paul Davis, Head of Communications, firstname.lastname@example.org